BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase II (World)
Alcobra (ADHD) Announces Enrollment Of First Patient In Phase 2b Clinical Trial Of MDX In Fragile X Syndrome 8/19/2014
NeuroVive Pharmaceutical ABl: Enrollment To Phase 2 Study On NeuroSTAT® Continues 8/15/2014
Austrianova Release: Human Clinical Trials Confirm Safety And Efficacy Of Encapsulated Cell Treatment For Pancreatic Cancer 8/15/2014
Phosphagenics Limited (POH.AX) Completes First IND Enabling Study For TPM(R) / Oxymorphone Patch 8/11/2014
Concordia Healthcare Corp (CXR.TO) Announces First Patients Enrolled In Phase 2 Clinical Trial Using Photodynamic Therapy With PHOTOFRIN(R) For Patients With Mesothelioma 8/11/2014
Alcobra (ADHD) Releases New Neuroimaging Data Supporting Pro-Cognitive Effects Of MDX 8/8/2014
Celsus Therapeutics (CLTX) Announces First Patient Enrolled In Phase 2 Trial Of MRX-6 In Pediatric Atopic Dermatitis 8/6/2014
Amarantus BioSciences, Inc. Announces Positive Top-Line Interim Clinical Data For Alzheimer's Blood Diagnostic Lympro Test® 8/4/2014
Amarantus BioSciences, Inc. Amends LymPro LP-002 Clinical Protocol to Report Interim Data at Presentation 7/30/2014
BioTie Therapies Corp. Updates Outlook On Tozadenant And SYN120 7/30/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1103 Acromegaly Phase 2 Trial Dosing Completed 7/29/2014
MorphoSys AG Provides Update On The Company's Proprietary Drug Portfolio 7/28/2014
Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 7/28/2014
Retroscreen Conducts Landmark hVIVO Human Challenge Model Study Of AL-8176 In RSV For Alios BioPharma 7/28/2014
GANYMED Pharmaceuticals AG Completes Recruitment For Randomized Phase 2 FAST Trial Of IMAB362 For Gastroesophageal Cancer 7/22/2014
"MetaMax" LLC Maxwell Biotech Venture Fund's Portfolio Company MetaMax Announces Enrollment Of First Patients In Phase 1/2a Clinical Trial Of Its Lead Anticancer Drug MM-D37K 7/21/2014
Can-Fite BioPharma (CFBI) CEO To Deliver Scientific Presentation And Serve On Expert Panel At Purines 2014 In Bonn, Germany On July 23-27, 2014 7/21/2014
CASI Pharmaceuticals  (ENMD) To Start China Trial Of Cancer Drug 7/21/2014
Amarantus BioSciences, Inc. Discusses New Independent Peer-Reviewed Research Papers On MANF 7/18/2014
Roche (RHHBY) Alzheimer's Drug Crenezumab Fails Main Goals In Phase 2 Study 7/17/2014
Consortium Of Food Allergy Research Completes Recruitment Of National Institutes of Health (NIH)-Sponsored Cofar6 Phase 2Trial With DBV Technologies's Viaskin® Peanut In Treatment Of Peanut Allergy 7/17/2014
DBV Technologies Completes Last "Food Challenge" Visit Of Last Peanut-Allergic Patient In VIPES Phase 2b Clinical Study 7/17/2014
BioTie Therapies Corp. Selects Bracket's CDR System™ For Phase 2 Trial Of Treatment Of Parkinson's Disease 7/16/2014
Amarillo Biosciences (AMAR) Announces Positive Analytical Performance Data Poster Presentation For Lympro Test At AAIC 2014 7/14/2014
Astellas Pharma Inc. (ALPMY) Details Pipeline Progress At R&D Meeting 7/11/2014
Helsinn Announces That Phase 2/3 Pivotal Trials For NEPA (Netupitant 300 Mg + Oral Palonosetron 0.50 Mg), Will Be Published In The Annals Of Oncology 7/10/2014
Pluristem Therapeutics (PSTI) Initiates South Korean Arm of Multinational Phase 2 Intermittent Claudication Trial 7/8/2014
BioTie Therapies Corp.: Tozadenant Phase 2b Parkinson's Disease Study Published In Lancet Neurology 7/8/2014
Dignity Sciences Release: DS107E-02 - Positive Phase 2 Results In Atopic Dermatitis 7/8/2014
Pharma Two B Ltd. Expands List Of Clinical Sites Enrolling For Phase IIb Study Of P2B001 For PD To 25 7/2/2014
Hanmi Pharmaceutical, Co., Ltd And Collaborative Partner Kinex Pharmaceuticals Report Encouraging Results On Oraxol® For Patients With Advanced Gastric Cancer From A Phase I/II Clinical Study 6/30/2014
TiGenix Announces The Clinical Development Of Cx611 In Early Rheumatoid Arthritis And Severe Sepsis 6/30/2014
Basilea Pharmaceutica (BSLN.SW) Announces Start Of Phase 2a Study With Oncology Drug Candidate BAL101553 6/26/2014
Bone Therapeutics Starts Patient Treatment In First Ever Clinical Trial With Allogeneic Bone Cell Therapy Product 6/25/2014
EnGeneIC Pty Ltd Unveils Clinical Development Strategy for EDV™ Nanocell Technology 6/24/2014
Protalix Biotherapeutics, Inc. (PLX) Announces New Data On ELELYSO™ (Taliglucerase Alfa) And Oral GCD To Be Presented At The European Working Group On Gaucher Disease 2014 11th Meeting 6/23/2014
VBL Therapeutics Announces Completion Of Enrollment In Phase 2 Clinical Studies Of VB-201 In Psoriasis And Ulcerative Colitis 6/20/2014
Neurim Pharmaceuticals Announces Publication Of Positive Effects Of Add-On Circadin® In Alzheimer's Disease Patients 6/19/2014
Protalix Biotherapeutics, Inc. (PLX) Initiates Phase 2 Study With PRX-112, An Orally-Administered Enzyme Replacement Therapy For The Treatment Of Gaucher Disease 6/18/2014
Celsus Therapeutics (CLTX) Receives Approval From The Ministry Of Health Of Israel For Phase 2 Trial Of MRX-6 In Pediatric Atopic Dermatitis Patients 6/17/2014
Zealand Pharma  (ZEAL.CO) Provides Summary Of New Clinical Data And Information On Lyxumia® (Lixisenatide) And Lixilan Presented At The American Diabetes Association’s 74th Scientific Sessions 6/17/2014
Senhwa Biosciences Initiates Phase 1/2 Trial Of CX-4945 In Combination With Gemcitabine And Cisplatin 6/17/2014
Grifols Completes Patient Enrollment In Its Phase2/3 Psoriasis Trial; Final Results Are Expected In Q1 2015 6/17/2014
Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy And Safety In Ground-Breaking Phase II Trigeminal Neuralgia Study 6/16/2014
ALK-Abello A/S’s Partner For Japan Announces Trial Results For House Dust Mite SLIT-Tablet 6/16/2014
Astex Pharmaceuticals (ASTX) Presents Final Results Of Phase 2 Study Of SGI-110 In Treatment Naïve Elderly Acute Myeloid Leukemia At The European Hematology Association Meeting 6/16/2014
Generex Biotechnology Corporation (GNBT)/Antigen Express, Inc. (GNBT) Announce Interview Of MD Anderson Cancer Center's Dr. Elizabeth Mittendorf, Principal Investigator On Company's AE37 Phase IIb Breast Cancer Efficacy Trial 6/12/2014
Umecrine Mood's Premenstrual Dysphoric Disorder (PMDD) Drug Fails Phase 2 Study 6/12/2014
Pfizer Inc. (PFE) To Showcase Over 10 Abstracts For XELJANZ® At Major Conference 6/11/2014
OphthaliX Inc. Provides An Update On Its Clinical Developments And Strategic Plans 6/9/2014
PsiOxus Therapeutics Limited Announces Positive Study Results Of Oncolytic Vaccine Enadenotucirev At 2014 American Society of Clinical Oncology Annual Meeting 6/3/2014
Jazz Pharmaceuticals plc (JAZZ) Presents JZP-110 Phase 2b Data For The Treatment Of EDS Symptoms In Adults With Narcolepsy 6/3/2014
Novartis AG (NVS)'s Drug Zykadia™ Shrank Tumors In Phase 1 Study 6/3/2014
Can-Fite BioPharma (CFBI) Announces That The FDA Has Agreed With Its Phase 2 Liver Cancer Protocol 6/2/2014
NOXXON Pharma AG’s Emapticap Pegol Study Selected For Late Breaking Clinical Trials Symposium During ERA-EDTA Conference 6/2/2014
D-Pharm Ltd. Reports Completion Of The Second Dose Tier In Its Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With The Thrombolytic Drug tPA 6/2/2014
BioTie Therapies Corp.: Nepicastat Study In Cocaine Dependence Completes Enrollment Ahead Of Schedule - Top-Line Data Expected Around End 2014 5/27/2014
TRANSGENE (ENX:TNG) Announces Promising Results In An Update From The Phase 2b Part Of TIME Trial With TG4010 In Advanced Non-Small Cell Lung Cancer 5/27/2014
Edison Pharmaceuticals, Inc.'s EPI-743 Granted Orphan Designation For Leigh Syndrome In Japan 5/21/2014
MediWound (MDWD) Initiates Second Phase 2 Clinical Trial Of Escharex™ To Treat Chronic And Other Hard-To-Heal Wounds 5/21/2014
MorphoSys AG's MOR208 Program To Receive Orphan Drug Designation From FDA And European Medicines Agency For The Treatment Of CLL/SLL 5/20/2014
Sanofi Pasteur (SASY.PA) Announces Favorable Phase 2 Study Results For Investigational Clostridium difficile Vaccine At The American Society for Microbiology Meeting 5/19/2014
Juventas Therapeutics, Inc. Data Demonstrates Significant Structural, Clinically Meaningful Benefit In Patients With Advanced Heart Failure 5/19/2014
Pluristem Therapeutics (PSTI) Receives Clearance From South Korea To Use PLX Cells Manufactured At Its New Facility In Its Advances Studies 5/19/2014
Kamada Ltd. (KMDA) Crashes After Key Trial Failure 5/19/2014
Telormedix' Vesimune Successfully Completes Phase 2 For Carcinoma In Situ Of The Bladder 5/16/2014
AstraZeneca PLC (AZN) Touts Success In 2 Phase 2 Studies 5/15/2014
AstraZeneca PLC (AZN) Announces Results Of Phase 2b Studies 5/13/2014
AiCuris And Merck & Co., Inc. (MRK) Announce Publication In New England Journal Of Medicine Of Phase 2 Clinical Trial Results Of Investigational Antiviral Agent Letermovir In Bone Marrow Transplant Patients 5/8/2014
Alcobra (ADHD) Announces FDA Clearance Of Protocol For Phase 2b Study Of Metadoxine Extended Release (MDX) In The Treatment Of Fragile X Syndrome 5/8/2014
Biota Pharmaceuticals, Inc. Provides An Update On The Development Of Laninamivir Octanoate 5/1/2014
Can-Fite BioPharma (CFBI) Submits Protocol To FDA For Phase II Liver Cancer Study 4/29/2014
Bavarian Nordic (BAVA.CO) Announces First Patient Treated In A Phase 2 Study Evaluating Its Immunotherapy Candidate CV-301 In Bladder Cancer 4/28/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Scientific Publication Of Phase 2 Study Demonstrating Conversion From Twice-Daily Tacrolimus To Once-Daily Envarsus® In Liver Transplant Patients 4/28/2014
Veloxis Pharmaceuticals A/S (VELO) Announces Scientific Publication Of Phase 2 Study Demonstrating Conversion From Twice-Daily Tacrolimus To Once-Daily Envarsus® In Liver Transplant Patients 4/28/2014
Prima Biomed (PRR.AX)'s CAN-004 Phase 2 Trial For Cvac™ Commences Recruitment 4/28/2014
FDA Approves Commencement Of BrainStorm Cell Therapeutics Inc.'s Phase 2 ALS Clinical Trial In U.S. 4/28/2014
Kamada Ltd. (KMDA.TA) Announces Significantly Improved Infusion Rate For Glassia® 4/24/2014
Teva Pharmaceutical Industries Limited (TEVA) Release: Pride-HD Study Enrolling Patients Globally To Further Evaluate Pridopidine For The Symptomatic Treatment Of Huntington’s Disease 4/24/2014
Anergis Completes Enrolment In The Long-Term Efficacy Trial Of Lead Compound AllerT 4/23/2014
Galapagos NV (GLPG.BR) Release: GSK2586184 Met Primary Endpoint In Phase 2a Psoriasis Study 4/17/2014
Final Data From The Phase 2 COSMOS Study Of Janssen Research & Development's Once-Daily Simeprevir In Combination With Sofosbuvir Presented At The International Liver Congress™ 2014 Of The European Association For The Study Of The Liver (EASL) 4/14/2014
Cytos Biotechnology AG's Asthma Drug CYT003 Flunks Pivotal Phase 2b Study 4/14/2014
GenKyoTex S.A. 's GKT137831 Found To Reverse Fibrosis And Improve Survival In A Model Of Persistent Lung Fibrosis 4/10/2014
Gilead Sciences, Inc. (GILD) Announces Phase 2 Results For Two Investigational All-Oral Sofosbuvir-Based Regimens For The Treatment Of Chronic Hepatitis C 4/10/2014
BioLineRx Ltd. Announces Investigator-Initiated Study For Novel Chronic Myeloid Leukemia Treatment 4/10/2014
Alcobra (ADHD) Submits Protocol To FDA For Phase 2b Clinical Study Of Metadoxine Extended Release (MDX) In The Treatment Of Fragile X Syndrome 4/10/2014
Adocia Reports Positive Results From Phase 2a Clinical Study Of Ultra-Fast Acting Biochaperone® Lispro 4/9/2014
NOXXON Pharma AG Release: Anti-Hepcidin Spiegelmer® Lexaptepid Pegol Increases Hemoglobin In Subset Of Anemic Patients In Pilot Phase 2a Study 4/8/2014
Mologen AG (MOLGF.PK): DSLIM® Shows Superior Immunoactivation Capabilities 4/8/2014
Viralytics Ltd (VLA.AX) Release: Positive Interim Phase 2 Trial Results For CAVATAK™, Novel Cancer Immunotherapy 4/8/2014
Pfizer Inc. (PFE) Continues Its Streak, Phase 2 Breast Cancer Results Wows Investors And Researchers 4/8/2014
Alnylam Pharmaceuticals (ALNY) Receives Positive Opinion For Orphan Drug Designation In The European Union For ALN-Ttrsc, A Subcutaneously Delivered Rnai Therapeutic For The Treatment Of Transthyretin-Mediated Amyloidosis (ATTR) 4/2/2014
PRANA Biotechnology (PRAN) Tanks As Lead Drug Fails Alzheimer's Study 4/1/2014
Forest Laboratories, Inc. (FRX), Gedeon Richter Ltd. (RIG2.F) Tout Positive Phase 2b Bipolar Depression Data 3/31/2014
Published Analysis Confirms Positive Results From Auris Medical AG's Phase 2b Study With AM-101 In Treatment Of Acute Inner Ear Tinnitus 3/31/2014
Novartis AG (NVS)'s Rare Lung Cancer Drug Ceritinib Shows Positive Response In Study 3/27/2014
Forest Laboratories, Inc. (FRX), Gedeon Richter Ltd. (RIG2.F) Shows Off Positive Phase 2b Data For Cariprazine To Treat Depression 3/21/2014
Antisense Therapeutics Limited (ANP.AX) Release: ATL1103 Acromegaly Phase 2 Trial Recruitment Completed 3/21/2014
Bionomics Limited (BNO.AX) Sinks As Renal Cancer Drug Fails Key Phase 2 Test 3/19/2014
Ipsen (IPN.PA): Dysport Incontinence Treatment Phase 2a Trial Positive 3/18/2014
Pharma Two B Ltd. Commences Phase 2b Study Of Fixed Dose Combination Therapy “P2B001” For Parkinson’s Disease 3/18/2014
Asthma Leader GlaxoSmithKline (GSK) Faces Competition From Roche (RHHBY), AstraZeneca PLC (AZN), Sanofi (France) (SAN.PA), And Teva Pharmaceutical Industries Limited (TEVA) 3/18/2014
Can-Fite BioPharma (CFBI): Phase II Study Protocol To Treat Patients With Advanced Liver Cancer With CF102 Has Been Approved By The IRB In Israel 3/17/2014
Neovacs SA Announces Positive IDSMB Review Of The Phase 2b Study Of TNF-Kinoid In Rheumatoid Arthritis 3/12/2014
ALK-Abello A/S’s Partner For Japan Reports Positive Trial Results For House Dust Mite SLIT-Tablet 3/10/2014
Edison Pharmaceuticals, Inc. Announces Initiation Of EPI-743 Phase 2B/3 Leigh Syndrome Clinical Trial With Dainippon Sumitomo Pharma Co., Ltd. In Japan 3/10/2014
Roche (RHHBY) Drug Cuts Asthma Attacks, Improves Lung Function In Phase 2b Study 3/6/2014
Medivir AB (MVRBF) Release: SVR12 Results From A Phase 2a Study Evaluating Simeprevir And Daclatasvir In Hepatitis C Patients Of Genotype 1 Have Been Presented 3/5/2014
Galapagos NV (GLPG.BR), GlaxoSmithKline (GSK) Anti-Inflammatory Drug Pact Hits A Roadblock 3/4/2014
D-Pharm Ltd. Reports The Successful Interim Analysis Of Its Phase 2 Clinical Study Of THR-18 In Acute Stroke Patients Treated With The Thrombolytic Drug tPA 3/4/2014
Kamada Ltd. (KMDA.TA) Completes Enrollment In U.S. Pivotal Clinical Trial With Kamrab As A Post-Exposure Treatment For Rabies 3/4/2014
Genticel Reaches An Important Milestone By Launching Its Phase II Trial In Women Infected With High-Risk HPV Before The Appearance Of High Grade Cervical Lesions 3/4/2014
Atopix Shows Off Positive Phase 2b Results For Once Daily OC459 In Asthma 3/3/2014
Novartis AG (NVS)'s Experimental Skin Cancer Drug Meets Primary Endpoint In Pivotal Phase 2 Trial 2/21/2014
PRANA Biotechnology (PRAN) Soars As Brain Disorder Drug Succeeds In Phase 2 Trial; Stock Up +39.31% At Market Close (February 18, 2014) 2/19/2014
Galapagos NV (GLPG.BR) Completes Patient Recruitment In Proof Of Concept Study With GLPG0974 In Ulcerative Colitis 2/18/2014
Galapagos NV (GLPG.BR) Completes Patient Recruitment In Proof Of Concept Study With GLPG0974 In Ulcerative Colitis 2/17/2014
Ario Pharma Commences Phase 2a Trial Of TRPV1 Inhibitor For Cough Associated With Chronic Obstructive Pulmonary Disease 2/11/2014
Oramed Pharmaceuticals Inc. (ORMP) Submits Phase 2a Protocol To FDA For The Treatment Of Type 1 Diabetes With Its Oral Insulin Capsule 2/10/2014
AstraZeneca PLC (AZN) Takes On Merck & Co., Inc. (MRK) In Alzheimer's Drug Race 2/7/2014
Can-Fite BioPharma (CFBI) Submitted Phase II Study Protocol With CF102 To Treat Patients With Advanced Liver Cancer 2/6/2014
Targovax TG01 Immunotherapy Reaches Phase 2a In Operable Pancreatic Cancer 2/6/2014
Spinifex Pharmaceuticals ' Phase 2 Results Published In The Lancet Show EMA401 To Be Effective In Reducing Pain In Postherpetic Neuralgia 2/5/2014
Oramed Pharmaceuticals Inc. (ORMP) Announces Successful FDA Phase 2a Clinical Trial Results 1/30/2014
Galapagos NV (GLPG.BR) Release: First Clinical Centers Opened For Phase 2 Crohn's Study With GLPG0634 1/30/2014
Positive Spinal Disc Repair Trial Results Using Mesoblast Limited (MSB.AX) Adult Stem Cells 1/30/2014
Allergy Therapeutics plc: Short Course Immunotherapy Effective In Reducing Ragweed Pollen Allergy 1/27/2014
Prosonix Reports Positive Top-Line Results From Its Phase 2 Clinical Study With PSX1002 In Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) 1/23/2014
BioLineRx Ltd. Receives Orphan Drug Designation For Novel Stem Cell Mobilization Treatment 1/23/2014
D-Pharm Ltd. Completes Recruitment Of Patients Into The First Dosage Tier Of Its Phase 2 Study With THR-18 In Acute Stroke Patients Treated With tPA. 1/21/2014
Prima Biomed (PRR.AX) Revised CAN-004 Trial Of Cvact In Ovarian Cancer Approved In Belgium - First Regulator To Approve Amended CVact Clinical Trial Design 1/20/2014
ERYtech Pharma Announces Clinical Trial Authorizations In Finland And Spain For Its European Phase 2b Study In AML 1/15/2014
D-Pharm Ltd. Announces Recruitment Of The First Patient Into Its Phase 2 Clinical Trial With DP-B99 In Acute High-Risk Pancreatitis 1/14/2014
GlaxoSmithKline (GSK)'s Tafinlar Drug Gets FDA Breakthrough Therapy Designation 1/14/2014
Apogenix' APG101 Demonstrates Significant Prolongation Of Overall Survival In Biomarker-Positive Patients In Phase II Trial For The Treatment Of Recurrent Glioblastoma 1/13/2014
Medivir AB (MVRBF) Release: Interim Results (SVR4) From A Phase 2 All-Oral Combination Study Of Simeprevir And Samatasvir (IDX719) For The Treatment Of Hepatitis C 1/13/2014
EntreMed, Inc. (ENMD) Files New Drug Global Clinical Trial Application For ENMD-2076 With China CFDA 1/13/2014
Dezima Pharma Completes Patient Enrollment For TULIP Phase 2B Study With CETP Inhibitor TA-8995 1/13/2014
TRANSGENE (ENX:TNG) Announces Topline Preliminary Results From Phase 2b Part Of TIME Trial With TG4010 In Non-Small Cell Lung Cancer 1/9/2014
Positive Feedback From The Scientific Community For Anaconda Pharma's Phase 2a Data For AP611074 First Clinical Proof Of Concept For The Curative Treatment Of Condyloma 1/9/2014
Viralytics Ltd (VLA.AX) Release: Target Enrollment Achieved In CAVATAK™ USA Phase 2 Melanoma Trial With Excellent Interim Results 1/8/2014
Adocia Launches Phase 2a Clinical Trial For Its Ultra-Fast Acting Formulation Of Analog Insulin 1/6/2014
D-Pharm Ltd. Reports Enrollment Of First Patient Into Phase 2 Study Of THR-18 In Stroke Patients Treated With Tissue Plasminogen Activator (tPA) 1/2/2014
Cerenis Therapeutics, Inc.'s Cholesterol Drug CER-001 Fails In Mid-Stage Trial 1/2/2014
Axelar AB's Phase 2 Lung Cancer Study Data Does Not Impress 12/31/2013
Antisense Therapeutics Limited (ANP.AX) Release: Positive Results Achieved From Interim Analysis Of ATL1103 Phase II Trial 12/23/2013
BioSpecifics Technologies Corporation (BSTC) Announces Top-Line Data From Phase 2 Trial Of CCH For Canine Lipoma 12/23/2013
Can-Fite BioPharma (CFBI) Soars On Positive Phase 2 Rheumatoid Arthritis Study; Stock Up +19.23% At Market Close (Dec. 23, 2013) 12/23/2013
GlaxoSmithKline (GSK)'s Malaria Drug Wins FDA "Breakthrough" Status 12/23/2013
Oramed Pharmaceuticals Inc. (ORMP.OB) Announces Successful Results From Ex-US Pharmacokinetic Study Of Its Oral Insulin For The Treatment Of Type 1 Diabetes 12/20/2013
MicuRx Pharmaceuticals Expands Global Clinical Trial Program For Oral Antibiotic MRX-I 12/20/2013
Alcobra (ADHD) Release: FDA Grants Orphan Drug Status To Metadoxine In Fragile X Syndrome 12/19/2013
Octapharma AG Phase 2/3 Trial For The Targeted Treatment Of Relapsing Multiple Sclerosis Enrols First Patients 12/18/2013
NovaBiotics Ltd Initiates Development Of Orphan Drug In Cystic Fibrosis 12/17/2013
Biomay AG Successfully Completes Interim Analysis Of Phase 2 Study With The Innovative 3rd Generation Grass Pollen Allergy Vaccine BM32 12/16/2013
Alcobra (ADHD) Announces Highly Statistically Significant Positive Phase 2b Clinical Trial Results In Adults With Predominantly Inattentive Attention Deficit Hyperactivity Disorder 12/16/2013
BioLineRx Ltd. Announces Promising Initial Phase 2 Results Of Acute Myeloid Leukemia Treatment 12/16/2013
Medivir AB (MVRBF) Release: An All-Oral Phase 2a Study Combining Simeprevir, TMC647055 And JNJ56914845 In Hepatitis C Patients To Be Initiated 12/12/2013
Targeted Antibody, Immune Checkpoint Blocker Rein In Follicular Lymphoma 12/12/2013
Kamada Ltd. (KMDA.TA) Announces Completion Of Pivotal Phase 2/3 Clinical Trial In Europe And Canada Of Inhaled AAT To Treat Alpha-1 Antitrypsin Deficiency 12/11/2013
Preliminary Findings Of BrainStorm Cell Therapeutics Inc.'s Phase 2a Study Reported As "Extremely Optimistic" 12/10/2013
NOXXON Pharma AG Release: Interim Phase 2a Results For Spiegelmer® Olaptesed Pegol (NOX-A12) In CLL And MM Studies 12/9/2013
NOXXON Pharma AG Release: Interim Phase IIa Results For Spiegelmer Olaptesed Pegol (NOX-A12) In CLL And MM Studies 12/9/2013
Neovacs SA Succesfully Enrolls First Patients In Its Phase 2b Study Of Tnf-Kinoid For The Treatment Of Rheumatoid Arthritis 12/9/2013
Can-Fite BioPharma (CFBI) Anticipates Results From Two Clinical Trials 12/5/2013
Apogenix' APG350 Effectively Induces Apoptosis Of Tumor Cells Via TRAIL Pathway Independent Of Fc-gamma Cross-Linking 12/5/2013
Mesoblast Limited (MSB.AX) Reports Positive Type 2 Diabetes Trial Results 12/4/2013
InnaVirVax Initiates Phase 2 Clinical Trial Evaluating VAC-3S, A Therapeutic Vaccine Used In Combination With Standard Antiretroviral Therapy In Treatment Of HIV-Infection 12/2/2013
Galapagos NV (GLPG.BR) Announces GSK2586184 JAK1 Molecule Moves Into Phase 2 For Ulcerative Colitis 11/27/2013
Bone Therapeutics Treats First Patients In PREOB® Pivotal Phase IIb/III Trial For The Treatment Of Non-Union Fractures 11/26/2013
BioLineRx Ltd. Announces New Positive Results In Phase 2a Trial For Orally Available Inflammatory Bowel Disease Treatment 11/26/2013
Alcobra (ADHD) Announces New Findings On Diminished Abuse Potential Of Its Proprietary Drug Candidate, MG01CI 11/22/2013
Zealand Pharma  (ZEAL.CO) Advances Danegaptide, Its Novel Drug Candidate, Into A Phase 2 Clinical Proof-Of-Concept Study For Protection Against Reperfusion Injury In Patients With Myocardial Infarction 11/20/2013
Pluristem Therapeutics (PSTI) Receives Regulatory Approval To Extend Its Phase II Study of PLX-PAD Cells In The Treatment Of Intermittent Claudication To South Korea 11/13/2013
PsiOxus Therapeutics Limited Cancer-Wasting Drug Better Than Placebo In Phase 2 Study 11/13/2013
Revalesio Initiates Phase IIa Study of RNS60 in Multiple Sclerosis at University Hospital Zurich 11/11/2013
ERYtech Pharma Announces Positive DSMB Review Of Its Phase 2b Study In Acute Myeloid Leukemia 11/11/2013
GenKyoTex S.A. NOX Inhibitor GKT137831 Successfully Shown To Halt Diabetic Kidney Disease 11/11/2013
Amakem NV to Present Top-Line Clinical Results for its Lead Candidate, AMA0076, at Ophthalmology Innovation Summit at the American Academy of Ophthalmology Meeting 2013 11/7/2013
Shanghai Sundise Reports Positive Results From TCM Liver Fibrosis Trial 11/7/2013
Trophos Completes Pivotal Phase II/III Study of Olesoxime in Spinal Muscular Atrophy (SMA) 11/6/2013
Medivir AB (MVRBF) Release: Results From the COSMOS Study With Simeprevir and Sofosbuvir in Cirrhotic and Non-Cirrhotic HCV genotype 1 Patients Presented at American Association for Study of Liver Diseases 11/5/2013
AB Science (AB.PA) Release: Masitinib is Being Investigated in the Treatment of Amyotrophic Lateral Sclerosis (ALS) 11/5/2013
Serodus AS Enrolls First Patient in SER100 Phase 2a Isolated Systolic Hypertension Clinical Study 11/5/2013
Active Biotech AB (BTPC)'s Partner Teva Pharmaceutical Industries Limited (TEVA) Initiates a Further Clinical Trial in Multiple Sclerosis 11/4/2013
Alfact Innovation Announces Positive Clinical Trial Results for Treatment of AIH- and HBV- Related Acute-on-Chronic Liver Diseases 11/4/2013
GeNeuro Successfully Completes Phase 2a Clinical Study With Novel Approach to Treat Multiple Sclerosis 11/4/2013
Immunocore Limited Initiates Phase IIa Clinical Trial for IMCgp100 in Melanoma 10/31/2013
PRANA Biotechnology (PRAN)'s PBT2 Reverses Memory Loss in Normal Aging 10/31/2013
Anaconda Pharma: Scientific Breakthrough in HPV Treatment 10/31/2013
e-Therapeutics plc Starts Phase IIb Trial of ETS6103 in Major Depressive Disorder 10/31/2013
Addex Therapeutics (ADXN.SW) Licensee Completes Enrollment of 120 Patients in a Phase 2 Clinical Trial of ADX71149 for the Treatment of Anxious Depression 10/29/2013
Alexion Pharmaceuticals Inc. (ALXN) Scores Another Breakthrough Designation for Ultra-Rare Metabolic Disorder 10/29/2013
GENFIT Corp. (ALGFT) Release: GFT505: the DSMB Approves the Continuation of the Phase 2b Study in NASH 10/28/2013
National Institutes of Health (NIH)-Sponsored Consortium of Food Allergy Research (CoFAR) Starts a Phase 2 Clinical Study With DBV Technologies' Viaskin® Peanut in the Treatment of Peanut Allergy 10/24/2013
Immunology Data Further Underline the Positive Outcome of a Phase IIb Trial of Anergis' Birch Pollen Allergy Vaccine AllerT 10/21/2013
GANYMED Pharmaceuticals AG's IMAB362 Receives Orphan Drug Designation From FDA and European Medicines Agency for Pancreatic Cancer 10/21/2013
D-Pharm Ltd. Commences Phase 2 Study With THR-18 in Stroke Patients Treated With Tissue Plasminogen Activator (tPA) 10/16/2013
Esteve S.A. (Laboratorios Del Dr. Esteve S.A.) Announces Positive Results From Its Phase 2 Clinical Study of E-58425 in Acute Pain 10/16/2013